Holen Sie sich die Stockscreener-App
6.07
6.76%
-0.44
Handel nachbörslich:
6.07
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$6.51
Offen:
$6.45
24-Stunden-Volumen:
1.88M
Relative Volume:
1.42
Marktkapitalisierung:
$277.50M
Einnahmen:
$27.10M
Nettoeinkommen (Verlust:
$-24.31M
KGV:
-7.3133
EPS:
-0.83
Netto-Cashflow:
$-33.33M
1W Leistung:
-1.78%
1M Leistung:
-17.53%
6M Leistung:
-48.82%
1J Leistung:
-68.79%
1-Tages-Spanne:
$6.06
$6.4645
1-Wochen-Bereich:
$6.06
$7.08
52-Wochen-Spanne:
$5.68
$20.75
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Firmenname
Capricor Therapeutics Inc
Sektor
Branche
Telefon
(310) 358-3200
Adresse
10865 ROAD TO THE CURE, SAN DIEGO, CA
Vergleichen Sie CAPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
6.07 | 297.62M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-30 | Eingeleitet | Alliance Global Partners | Buy |
| 2025-06-26 | Eingeleitet | B. Riley Securities | Buy |
| 2025-05-20 | Eingeleitet | Roth Capital | Buy |
| 2024-10-21 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-26 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-01-26 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-13 | Fortgesetzt | Rodman & Renshaw | Buy |
| 2016-07-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-06-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten
Capricor Therapeutics Stock Becomes Talk Of Retail Town On DMD Study; Retail Sees New Hope After Sarepta Setback - Stocktwits
What valuation multiples suggest for Capricor Therapeutics Inc. stockPortfolio Update Report & Growth Oriented Trade Recommendations - newser.com
Capricor Therapeutics (CAPR) Advances DMD Treatment with New Res - GuruFocus
Chart based analysis of Capricor Therapeutics Inc. trendsTrade Risk Report & Fast Entry High Yield Stock Tips - newser.com
Strategies to average down on Capricor Therapeutics Inc.2025 Market Outlook & Weekly Top Gainers Alerts - newser.com
What insider purchases suggest about Capricor Therapeutics Inc. (4LN2) stockJuly 2025 Setups & Stepwise Trade Signal Implementation - newser.com
Capricor (NASDAQ: CAPR) publishes Deramiocel MOA; assay supports Phase 3 DMD - Stock Titan
Smart tools for monitoring Capricor Therapeutics Inc.’s price actionJuly 2025 Retail & AI Based Buy/Sell Signal Reports - newser.com
Is Capricor Therapeutics Inc. (4LN2) stock a momentum leader2025 Earnings Surprises & Low Risk Entry Point Guides - newser.com
Will Capricor Therapeutics Inc. price bounce be sustainableQuarterly Portfolio Review & Verified Momentum Watchlists - newser.com
Why Capricor Therapeutics Inc. stock is a must watch in 2025Weekly Trend Summary & Fast Moving Trade Plans - newser.com
Will Capricor Therapeutics Inc. (4LN2) stock outperform energy sector in 2025July 2025 Earnings & Trade Opportunity Analysis - newser.com
Price momentum metrics for Capricor Therapeutics Inc. explained2025 Trading Volume Trends & Long-Term Growth Stock Strategies - newser.com
What institutional flow reveals about Capricor Therapeutics Inc.July 2025 Catalysts & Verified Momentum Stock Ideas - newser.com
Will Capricor Therapeutics Inc. stock benefit from upcoming earnings reportsMarket Volume Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Capricor Therapeutics Inc.’s volatility index tracking explainedGap Up & Daily Growth Stock Tips - newser.com
Chart overlay techniques for tracking Capricor Therapeutics Inc.Weekly Trend Summary & Community Supported Trade Ideas - newser.com
Will Capricor Therapeutics Inc. (4LN2) stock see insider accumulationGlobal Markets & AI Forecast for Swing Trade Picks - newser.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Capricor Therapeutics, Inc. (CAPR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Is it too late to sell Capricor Therapeutics Inc.Market Movers & Community Driven Trade Alerts - newser.com
HBK Sorce Advisory LLC Increases Stake in Capricor Therapeutics, Inc. $CAPR - MarketBeat
Capricor Therapeutics Inc. stock trend outlook and recovery pathJuly 2025 WrapUp & Real-Time Volume Trigger Notifications - newser.com
Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10 - The Manila Times
Capricor Therapeutics to Announce Third Quarter 2025 Financial Results on November 10, 2025 - Quiver Quantitative
We're Hopeful That Capricor Therapeutics (NASDAQ:CAPR) Will Use Its Cash Wisely - Yahoo Finance
What technical charts say about Capricor Therapeutics Inc. stockEarnings Growth Summary & AI Driven Stock Movement Reports - newser.com
How big funds are accumulating Capricor Therapeutics Inc. (4LN2) stockPortfolio Performance Report & Free Fast Gain Swing Trade Alerts - newser.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to Reach Out - ACCESS Newswire
Capricor (CAPR) Moves 12.0% Higher: Will This Strength Last? - Yahoo Finance
Finanzdaten der Capricor Therapeutics Inc-Aktie (CAPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):